S&P 500 Snaps Losing Streak With Tax Hikes, Inflation Data on Horizon

The Dow Jones Industrial Average also advanced, but the Nasdaq Composite Index ended lower.

Investors favored value over growth, with stocks set to benefit most from a resurging economy enjoying the biggest percentage gains.

“There are probably not a lot of positive surprises coming this month,” said Liz Young, head of investment strategy at SoFi in New York. “We’re having another period of volatility where I think that rotation could go back to cyclicals and the reopened trade, as the 10-year bond rate slowly grinds higher through the end of the year.”

Market participants are focused on the likely passage of U.S. President Joe Biden’s $3.5 trillion budget package, which is expected to include a proposed corporate tax rate hike to 26.5% from 21%.

Goldman Sachs analysts see the corporate tax rate increasing to 25% and the passage of about half of a proposed increase to tax rates on foreign income, which they estimate would reduce S&P 500 earnings by 5% in 2022.

The Labor Department is due to release its consumer price index data on Tuesday, which could shed further light on the current inflation wave and whether it is as transitory as the Fed insists.

“I don’t see inflation settling back down under 2% where it was pre-pandemic,” Young added. “Even if some of those transitory forces weaken, we will still stay at a higher rate than we were before.”

Other key indicators due this week include retail sales and consumer sentiment, which could illuminate how much the demand boom driven by economic re-engagement has been dampened by the highly contagious COVID-19 Delta variant.

The Dow Jones Industrial Average rose 261.91 points, or 0.76%, to 34,869.63, the S&P 500 gained 10.15 points, or 0.23%, at 4,468.73 and the Nasdaq Composite dropped 9.91 points, or 0.07%, to 15,105.58.

Of the 11 major sectors in the S&P 500, healthcare suffered the largest percentage loss, while energy, buoyed by rising crude prices was the biggest gainer.

Shares of vaccine makers Moderna and Pfizer Inc sank 6.6% and 2.2%, respectively, after experts said COVID booster shots are not widely needed.

Coinbase Global Inc announced plans to raise about $1.5 billion through a debt offering aimed at funding product development and potential acquisitions. The cryptocurrency exchanges shares slid 2.2%.

Salesforce.com Inc dipped 1.2% as rival Freshworks Inc’s regulatory filing indicated that the business engagement and customer engagement software company is aiming for a nearly $9 billion valuation in it U.S. debut.

Advancing issues outnumbered declining ones on the NYSE by a 1.60-to-1 ratio; on Nasdaq, a 1.02-to-1 ratio favored advancers.

The S&P 500 posted 12 new 52-week highs and one new low; the Nasdaq Composite recorded 53 new highs and 71 new lows.

Volume on U.S. exchanges was 10.30 billion shares, compared with the 9.29 billion average over the last 20 trading days.

For a look at all of today’s economic events, check out our economic calendar.

(Reporting by Stephen Culp; Additional reporting by Krystal Hu in New York and Ambar Warrick in Bengaluru; Editing by Richard Chang)

The Shares Of Moderna Rally After The Company Introduces Single-Shot Vaccine Booster For Covid And Flu

The shares of Moderna are up by over 8% today after the company revealed a single-shot vaccine booster for Covid and flu.

Moderna develops a single-shot vaccine for Flu and Coronavirus

Moderna has been one of the best-performing companies in recent months. The company’s stock price soared higher today after it announced the single-shot vaccine booster for Covid and flu. The shot is expected to make things much easier for people.

The new vaccine, which Moderna calls mRNA-1073, combines the company’s current Covid vaccine with a flu shot that is currently being developed. CEO Stephane Bancel stated that “Today, we are announcing the first step in our novel respiratory vaccine program with the development of a single-dose vaccine that combines a booster against COVID-19 and a booster against flu.”

She added that Moderna is making progress on enrolling patients into their rare disease programs. Furthermore, the company is fully enrolled in its personalized cancer vaccine trial. The CEO said they believe this is the start of a new age of information-based medicines.

Moderna has been one of the leading companies in terms of Covid vaccine. The company recently launched its mRNA-based two-dose Covid vaccine after gaining approval from the Food and Drug Administration last year. So far, nearly 150 million Moderna shots have been administered in the United States.

Moderna’s Stock Price Is Up By More Than 8%

The shares of Moderna have been rallying since the company announced the launch of its single-shot vaccine booster for Covid and flu. MRNA is up by 8% so far today, making it one of the best-performing stocks in the market.

MRNA stock chart. Source: FXEMPIRE

MRNA is currently trading at $456 per share after its latest rally. Year-to-date, MRNA is one of the best-performing stocks in the market. It started in 2021 trading at $111 per coin, but it is now up by more than 300% since then.

Why Moderna Stock Is Up By 5% Today

Moderna Stock Rallies As U.S. Is Reportedly Ready To Offer Booster Shots

Shares of Moderna gained upside momentum after The New York Times reported that U.S. will soon announce that most Americans would need a booster shot of COVID-19 vaccine following eight months after their second shot.

Shares of other vaccine makers are also rallying today. Pfizer stock managed to get to all-time high levels and is trying to settle above $50. Johnson & Johnson stock is also testing new all-time highs while BioNTech rebounds after the recent sell-off.

Moderna stock is also boosted by UK decision to authorize its vaccine for people aged 12 – 17 years, which opens a new market for the company.

What’s Next For Moderna Stock?

Moderna stock has recently made an attempt to settle above the $500 level but lost momentum and pulled back towards the $350 level. The pullback was fast and brutal, but it should be noted that Moderna shares traded below the $250 level at the beginning of July, and some profit-taking was expected after the meteoric rise of the share price.

While the stock pulled back from highs, analyst earnings estimates have increased materially. Currently, analysts expect that Moderna will report earnings of $29.54 per share in 2021 and $23.46 per share in 2022, so the stock is trading at about 17 forward P/E.

Rising analyst estimates may provide additional support to Moderna shares in the upcoming trading sessions, and it looks that there is more room for multiple expansion as Moderna stock has returned to valuation levels below 20 forward P/E.

While the situation with coronavirus is going in the wrong direction for the world, it is clearly developing in a favorable fashion for vaccine makers. If U.S. introduces booster shots, other developed countries will likely follow, and vaccine prices may increase further due to significant competition for a limited number of vaccine shots. At this point, it looks that Moderna stock has a good chance to continue its current rebound.

For a look at all of today’s economic events, check out our economic calendar.

Pfizer, Moderna Seen Reaping Billions from COVID-19 Vaccine Booster Market

For several months, the companies have said they expect that fully inoculated people will need an extra dose of their vaccines to maintain protection over time and to fend off new coronavirus variants.

Now a growing list of governments, including Chile, Germany and Israel, have decided to offer booster doses to older citizens or people with weak immune systems in the face of the fast-spreading Delta variant.

Late on Thursday, the U.S. Food and Drug Administration authorized a booster dose of vaccines from Pfizer Inc and Moderna Inc for people with compromised immune systems.

Pfizer, along with its German partner BioNTech, and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations.

Going forward, analysts have forecast revenue of over $6.6 billion for the Pfizer/BioNTech shot and $7.6 billion for Moderna in 2023, mostly from booster sales. They eventually see the annual market settling at around $5 billion or higher, with additional drugmakers competing for those sales.

The vaccine makers say that evidence of waning antibody levels in vaccinated people after six months, as well as an increasing rate of breakthrough infections in countries hit by the Delta variant, support the need for booster shots.

Some early data suggests that the Moderna vaccine, which delivers a higher dose at the outset, may be more durable than Pfizer’s shot, but more research is needed to determine whether that is influenced by the age or underlying health of the people vaccinated.

As a result, it is far from clear how many people will need boosters, and how often. The profit potential of booster shots may be limited by the number of competitors who enter the market. In addition, some scientists question whether there is enough evidence that boosters are needed, particularly for younger, healthy people. The World Health Organization has asked governments to hold off on booster shots until more people worldwide receive their initial doses.

“We don’t know what the market forces will be,” Moderna President Stephen Hoge said in an interview last week. “At some point, this will become a more traditional market – we’ll look at what are the populations at risk, what value are we creating, and what are the number of products that serve that value. That will ultimately impact price.”

Pfizer declined to comment for the story. During the company’s second-quarter earnings call, executives said they believe a third dose will be necessary 6 to 8 months after vaccination, and regularly afterward.

    A MODEL IN FLU SHOTS

If regular COVID-19 boosters are needed among the general population, the market would most resemble the flu shot business, which distributes more than 600 million doses per year. Four competitors split the U.S. flu market, which is the most lucrative and accounts for around half the global revenue, according to Dave Ross, an executive at CSL’s flu vaccine unit Seqirus.

Flu vaccination rates in developed countries have settled at around 50% of the population, and COVID boosters would likely follow a similar pattern if approved widely, said Atlantic Equities analyst Steve Chesney.

Flu shots cost around $18 to $25 a dose, according to U.S. government data and competition has kept price increases in check, with producers raising prices 4 or 5 percent in 2021.

Pfizer and Moderna may have greater pricing power for their boosters, at least at the outset, until competitors arrive. Pfizer initially charged $19.50 per dose for its vaccine in the United States and 19.50 euros for the European Union, but has already raised those prices 24% and 25%, respectively, in subsequent supply deals.

AstraZeneca Plc and Johnson & Johnson are both gathering additional data on boosters of their vaccines. Novavax, Curevac, and Sanofi could also potentially be used as boosters, though their vaccines have yet to receive any regulatory authorization.

“A lot of these firms aren’t even in the market yet. I think within a year’s time, all these companies will have booster strategies,” said Morningstar analyst Damien Conover, who covers Pfizer.

Mizuho Securities analyst Vamil Divan expects at least 5 players in the COVID-19 booster market within a few years.

There’s still a lot of uncertainty around how boosters would be rolled out in the United States. Still, it is possible or even likely that people will be boosted with different vaccines than they were originally vaccinated with. The National Institute of Allergy and Infectious Diseases is already testing mixed boosting, and other countries that have used so-called mix and match vaccination have not had problems with that strategy.

One factor that could curb prices is if the U.S. government continues paying for most or all of the shots administered in the country, rather than leave it in the hands of private health insurers. In that scenario, the government would still be negotiating prices directly with vaccine makers, and could use its buying power to stave off price increases.

Bijan Salehizadeh, managing director at healthcare investment firm Navimed Capital, said the U.S. government is likely going to want to keep paying in order to keep vaccination rates high and prevent new COVID surges, particularly if a Democratic administration is still in power.

“It’s going to be paid for until the virus disappears or mutates to be less virulent,” Salehizadeh said.

For a look at all of today’s economic events, check out our economic calendar.

(Reporting by Michael Erman, Additional reporting by Julie Steenhuysen in Chicago and Carl O’Donnell in New York; Editing by Michele Gershberg, Nick Zieminski and Keith Weir)

Pfizer Shares Hit Record High With COVID-19 Vaccine Stocks on a Tear

Pfizer shares were last up 4.9% at $48.25, climbing as high as $48.57 during the session. The stock’s previous intraday high was $47.44, reached on April 12, 1999.

The percentage gain was the stock’s biggest one-day rise since Nov. 9, when Pfizer released positive data for its COVID-19 vaccine.

“I think they are finally getting credit for the vaccine,” said Jeff Jonas, a portfolio manager at Gabelli Funds, which owns Pfizer shares.

While investors had treated the vaccine before as “a one-time cash infusion … it is really going to be a durable business, unfortunately,” Jonas said, adding that Pfizer should be able to leverage the vaccine’s technology for use against other types of disease as well.

Pfizer’s share gains come as those of another coronavirus vaccine maker, Moderna Inc, have also been on a tear.

While Moderna’s shares were down 4% on Tuesday, they have soared some 78% since mid July, when S&P Dow Jones Indices announced it was adding the biotech company’s stock to the benchmark S&P 500 index.

U.S.-traded shares of Pfizer’s partner on the vaccine, Germany’s BioNTech, were down over 5% on Tuesday, but have climbed about 30% this month.

Shares of Novavax, which last week delayed its timeline for its COVID-19 vaccine, were up 11% on Tuesday.

The rapid spread of the Delta variant of the coronavirus has pushed cases and hospitalizations in the United States to a six-month high.

“The Delta variant has scared a lot of people into getting inoculated,” said Peter Tuz, president of Chase Investment Counsel and an investor in Pfizer.

Pfizer in late July raised its 2021 sales forecast for its COVID-19 vaccine by 29% to $33.5 billion.

Ashtyn Evans, a healthcare analyst at Edward Jones, said Pfizer will be able to use the cash flow from the vaccine “for both internal research and development and for acquisitions to strengthen their pipeline.”

For a look at all of today’s economic events, check out our economic calendar.

(Additional reporting by Noel Randewich in San Francisco; Reporting by Lewis Krauskopf; Editing by Marguerita Choy)

Moderna To Build A Covid Vaccine Manufacturing Plant In Canada

Leading pharmaceutical company Moderna has revealed that it has reached a deal with the Canadian government to build a manufacturing plant to make Covid-10 vaccines.

Moderna Finalizes Covid Manufacturing Plant Deal With Canada

Moderna announced earlier today that it had reached a deal with the Canadian government to build a “state-of-the-art” manufacturing plant. The plant would be used to manufacture Covid-19 vaccines after the country suffered shortages earlier this year.

According to Moderna, the plant would also be used to manufacture shots for other potential respiratory viruses. The plant will make it easy for Canadians to gain access to domestically manufactured Covid vaccines. In addition to that, they would gain access to other vaccines, including that of seasonal influenza, respiratory syncytial virus and more.

Patricia Gauthier, Moderna’s lead for Canadian operations, stated, “We are excited to expand our presence and continue our long-term collaboration with Canada. With our industry-leading mRNA technology platform and rapid drug development capabilities, we look forward to being an active participant in Canada’s robust life sciences ecosystem.”

Moderna intends to help Canada with direct access to vaccines in times of health emergencies. The pharmaceutical giant said it doesn’t intend to stop with Canada as it is currently discussing similar collaborations with other governments.

MRNA Up By Over 300% Year-To-Date

Moderna is one of the best-performing stocks so far this year. Thanks to the company’s role in developing the Coronavirus vaccine, the shares of Moderna are up by more than 300% year-to-date.

MRNA stock chart. Source: FXEMPIRE

MRNA began 2021 trading at $111. However, Moderna’s stock has rallied over the past few months, and it is currently trading at $467. MRNA is down by 3.75% since the US market opened a few hours ago, despite the news of its deal with the Canadian government. The market could still react to the Canadian news, and this could push the stock price past the $475 mark in the coming hours or days.

Why Moderna Stock Is Down By 5% Today

Moderna Stock Falls As Traders Take Profits At All-Time High Levels

Moderna stock made an attempt to get to the test of the $500 level but lost momentum and pulled back closer to $450.

The stock got an additional boost after recent reports suggested that Moderna’s vaccine was more effective against the Delta variant of coronavirus compared to the vaccine developed by BioNTech and Pfizer.

According to the reports, the efficacy of Moderna’s vaccine declined to 76% in July while the efficacy of Pfizer/BioNTech dropped to just 42%.

However, Moderna stock declined despite these new reports as traders decided to take profits near the psychologically important $500 level.

What’s Next For Moderna Stock?

Moderna shares have lost some momentum due to profit-taking, but the stock’s  fundamental story remains strong.

It is increasingly likely that countries will have to use booster shots in order to protect their citizens against COVID-19 which means that Moderna will get more revenue in the upcoming years.

Analysts expect that Moderna will report earnings of $18.2 per share in 2022 so the stock is trading at roughly 25 forward P/E, but analyst estimates may move higher in the upcoming weeks as demand for vaccines stays very strong.

The main risk for the stock right now is a potential pullback caused by profit-taking, but it should be noted that stocks easily get to “overbought” levels and continue to move higher when demand is strong. The market will likely focus on the topic of booster vaccines in the upcoming weeks, and demand for Moderna shares may increase even more.

In the longer-term, the key question is whether demand for Moderna’s coronavirus vaccine will be sufficient enough in the next years to justify current stock price levels. However, the market will likely focus on near-term developments as the world continues its battle against coronavirus, so thoughts about long-term earnings potential will likely have minimal impact on Moderna’s stock price dynamics this year.

For a look at all of today’s economic events, check out our economic calendar.

Why Moderna Stock Tested New Highs Today

Moderna Shares Keep Moving Higher After Strong Quarterly Report

Shares of Moderna gained strong upside momentum after the company reported its quarterly results and made an attempt to settle above $444.

Moderna reported revenue of $4.4 billion and GAAP earnings of $6.46 per share, easily beating analyst estimates on both earnings and revenue. The company noted that recent data suggested that its vaccine had 93% efficacy which remained durable through six months after the second dose.

Moderna noted that its dose capacity for COVID-19 vaccine in the full-year 2021 was between 800 million and 1 billion. In 2022, dose capacity is expected to increase to 2 billion – 3 billion, and the company has already signed advance purchase agreements for $12 billion.

Not surprisingly, the company’s Board authorized a share repurchase program of up to $1 billion over a two-year period, although it remains to be seen whether the company will begin to immediately repurchase its stock at current levels.

What’s Next For Moderna Stock?

Moderna stock continues to rally as the quarterly report indicates that the company enjoys financial success. Moderna has easily beaten analyst estimates, and its financial results will get even better in the upcoming quarters as demand for COVID-19 vaccines remains strong.

WHO has recently asked developed countries to drop plans for booster shots of COVID-19 vaccines at a time when poorer countries had serious problems with access to vaccines, but this plea will likely fall on deaf ears.

Thus, Moderna and other vaccine makers will enjoy strong demand from both developed countries, who need booster shots, and developing countries, who struggle to get any vaccines.

The key risk for Moderna’s shares right now is a pullback which may be triggered by profit taking. The stock started the year near the $100 level, and it has recently made an attempt to get to the test of the $450 level. In this light, traders should be cautious with new positions before a material pullback occurs.

For a look at all of today’s economic events, check out our economic calendar.

Johnson & Johnson Completes Breakout Pattern

Dow component Johnson & Johnson (JNJ) is trading higher by 1% in Wednesday’s pre-market session after beating Q2 2021 top and bottom line estimates and raising fiscal year 2021 guidance. The pharmaceutical and home health care giant earned $2.48 per-share during the quarter, $0.19 better than expectations, while revenue rose an impressive 27.1% year-over-year to $23.31 billion, nearly $800 million higher than consensus.

Fighting Off Bad Press

The company dealt with a wave of misinformation about the Janssen vaccine and potential for side effects in the first half of the year. The negative news flow has damped sales, with just 13 million doses administered to date, compared to around 330 million for Pfizer Inc. (PFE) and Moderna Corp. (MRNA).  Even so, quarterly product sales grew 10% and these controversies aren’t the tipping point for the $447 billion mega cap with 2.63 billion shares outstanding.

Johnson & Johnson faces a bigger challenge with ongoing talcum powder and opiate litigation.  It’s just finalized a $26 billion opioid settlement with more than 40 states and may attempt to “rope off” potential talc exposure into a separate entity that can be taken through bankruptcy proceedings. However, that could be a hard sell for U.S. courts flipping through the balance sheet of the 12th largest publicly traded corporation.

Wall Street and Technical Outlook

Wall Street consensus hasn’t budged in 2021 despite front page headlines, with an ‘Overweight’ rating based upon 12 ‘Buy’, 3 ‘Overweight’, 4 ‘Hold’, and 1 ‘Underweight’ recommendation. Price targets currently range from a low of $160 to a Street-high $203 while the stock is set to open Wednesday’s session about $18 below the median $188 target. Strong price action so far in 2021 suggests that gains will stretch into the median target by year’s end.

Johnson & Johnson broke out above February 2020 resistance near 150 in January 2021, entering a strong uptrend that posted an all-time high at 173.65 a few weeks later. Price action since that time has carved the outline of a bullish ascending triangle pattern that forecasts a measured move target in the 190s following a breakout. However, that event could take time to unfold because selling pressure in the last seven weeks has weakened an otherwise solid technical outlook.

For a look at all of today’s economic events, check out our economic calendar.

Disclosure: the author held no positions in aforementioned securities at the time of publication. 

Why Moderna Stock Keeps Moving Higher

Moderna Shares Test All-Time High Levels

Moderna stock gained huge upside momentum after the stock was included into S&P 500 and continues to move higher. The stock, which has recently traded below the $240 level, is currently trying to settle above the $340 level, having gained more than 40% in just 5 trading sessions.

The recent market worries about the spread of the Delta variant of coronavirus served as an additional bullish catalyst for Moderna shares. Countries rush to secure new doses of vaccines which means that Moderna has good chances to get solid revenue in the upcoming years.

In a latest deal, Takeda Pharmaceutical agreed to supply 50 million does of Moderna’s vaccine to Japan. The extra doses could be supplied at the beginning of 2022. Similar deals may follow as more countries open up to the idea of booster doses, which is bullish for Moderna and other vaccine makers.

What’s Next For Moderna Stock?

Analyst estimates for Moderna’s earnings have not changed in recent days, and the stock is currently trading at almost 19 forward P/E for 2022, which is a major increase compared to 13 forward P/E which was seen at the end of June.

Valuation is getting stretched, and traders should keep in mind that the market does not have good earnings visibility beyond 2022 as the trajectory of the pandemic is not known.

The forced buying from index funds who purchase Moderna shares because they were included into S&P 500 will soon end, and this factor will be out of play.

Technically, RSI is in the extremely oversold territory, and the risks of a pullback are increasing day by day.

All in all, it looks that traders should be prepared for a pullback in Moderna shares due to both fundamental and technical factors. The company’s market capitalization has increased significantly without any increase in earnings estimates, and traders will soon begin to take some profits off the table after the major rally.

For a look at all of today’s economic events, check out our economic calendar.

Moderna’s Shares Up By 8% After Addition to S&P 500

The shares of Moderna are rallying today after news emerged that the company would be included in the S&P 500, replacing Alexion Pharmaceuticals, which is being acquired by AstraZeneca (AZN).

Moderna To Enter The S&P 500

Biotech company Moderna is already popular throughout the globe after playing a key role in developing the Coronavirus vaccine. The company is set to get even more popular after it was announced that it would be included in the S&P 500 index.

Moderna is set to replace drugmaker Alexion Pharmaceuticals, which is expected to be acquired by Big Pharma giant AstraZeneca soon. S&P 500 said the changes would come into effect before the market opens by next Wednesday

The biotech company manufactures one of the three Covid-19 vaccines approved by the United States Food and Drug Administration (FDA). It is joined by Pfizer (PFE) and BioNTech (BNTX), who manufacturer a two-dose vaccine similar to Moderna’s. Meanwhile, Johnson & Johnson (JNJ) offers a single-dose Covid shot.

Moderna’s Shares Are Rallying

The shares of Moderna have been rallying since the news broke that it would be joining the S&P 500. At the time of this writing, Moderna (MRNA) is up by 8% at Friday’s trading session and could soar higher over the coming hours.

MRNA stock chart. Source: FXEMPIRE

Year-to-date, Moderna’s stock price has gone up by nearly 175%, with the company now having a valuation of over $100 billion. Its addition to the S&P 500 means will see a wide range of passively managed funds and exchange-traded funds (ETFs) that reflect the performance of the S&P 500 add the Moderna stock to its portfolio. This would increase the company’s exposure and allow more institutional investors to access it. This is the key reason why the stock has been performing excellently today.

With more vaccines needed globally to fight the pandemic, Moderna’s stock price could experience further gains over the coming months.

Why Moderna Stock Is Up By 9% Today

Moderna Stock Tests New Highs As It Is Included Into S&P 500

Moderna shares gained strong upside momentum and moved to new all-time high levels after the stock was included into S&P 500. Moderna would join S&P 500 on July 21 and replace Alexion Pharmaceuticals.

Inclusion into S&P 500 is a powerful catalyst for a stock as funds that follow the index are obliged to buy Moderna shares. In this light, it is not surprising to see that Moderna stock is up by 9% in just one trading session.

In addition, the spread of the Delta variant of coronavirus continues to serve as a bullish catalyst for vaccine makers. While health officials from U.S. and EU have recently stated that it was too early to talk about whether booster doses of COVID-19 vaccines would be needed, the market begins to price in the increased likelihood of significant revenue from COVID-19 vaccines in the upcoming years.

What’s Next For Moderna Stock?

As traders witnessed at the end of 2020 in the case of Tesla, an inclusion of a hot stock into S&P 500 can be a very significant upside catalyst. Speculative traders rush to buy such stocks as they know that funds that follow the index will be forced to buy shares at any price.

In Moderna’s case, the bullish thesis is supported by the challenging situation on the coronavirus front. WHO has recently announced that the world was in the early stage of the third wave of coronavirus which signals that demand for COVID-19 vaccines may be strong for years to come.

Interestingly, analyst estimates for Moderna’s earnings have declined in recent weeks. Currently, analysts expect that Moderna will report earnings of $24.57 per share in 2021 and earnings of $18.2 per share in 2022.

At current levels, the stock is trading at roughly 16 forward P/E which is more expensive compared to the recent levels as the stock price has increased materially in recent weeks while analyst estimates declined.

However, the inclusion into S&P 500 is a very strong positive factor, and Moderna’s shares have a decent chance to continue their upside move in the upcoming trading sessions.

For a look at all of today’s economic events, check out our economic calendar.

Dollar Makes a Move

The Chinese composite PMI unexpectedly fell from 54.2 to 52.9 earlier this morning with details showing a stabilisation of the manufacturing gauge but a setback in the non-manufacturing reading. New restrictive measures in Gaundong to contain a regional Covid outbreak are mainly responsible for this with waning external demand contrasting with rising domestic orders.

Risk mood improved

Markets took comfort in Moderna saying that its vaccine is effective against the Delta variant of the virus with the S&P500 marginally higher and closing at all-time highs. The tech-laden Nasdaq also notched another record peak rising for a sixth day in seven with Facebook pulling back after hitting the magical $1 trillion market cap level. Also adding to more positive sentiment was the US Consumer confidence which jumped with a bounce both in expectations and the current situation.

The dollar went bid breaking out of its recent range and is heading towards the post-Fed highs.

In EUR/USD, this means we are trading below 1.19 again with eyes on the recent cycle lows at 1.1847.

With the monthly US labour market report out on Friday, focus will be on US ADP data today which will be monitored for any signs that private sector hiring has quickened. Although not a great predictor of the NFP headline number, a big beat or miss today can cause near-term volatility. Expectations are for a punchy 600k reading with many analysts hopeful that jobs data comes in strong going forward.

Eurozone inflation subdued

Consensus expects headline and core Eurozone inflation prints to remain relatively subdued at 1.9% y/y and 0.9% y/y respectively when the data is released this morning. Country figures already pointed to a slowdown and these are fairly tame readings compared to those elsewhere. With the outlook remaining muted, the ECB will continue to be one of the last remaining dovish central banks on the block.

Written on 30/06/2021 by Lukman Otunuga, Senior Research Analyst at FXTM

For more information, please visit: FXTM


Disclaimer: This written/visual material is comprised of personal opinions and ideas. The content should not be construed as containing any type of investment advice and/or a solicitation for any transactions. It does not imply an obligation to purchase investment services, nor does it guarantee or predict future performance. FXTM, its affiliates, agents, directors, officers or employees do not guarantee the accuracy, validity, timeliness or completeness of any information or data made available and assume no liability for any loss arising from any investment based on the same.

Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 81% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Why Moderna Stock Is Up By 6% Today

Moderna Stock Rallies To New Highs Amid Concerns About Delta Variant Of Coronavirus

Shares of Moderna have set a new record as traders rushed to buy the company’s shares amid concerns about Delta variant of coronavirus.

The Delta variant has spread from India to many countries in the world, and some countries have already been forced to introduce new virus containment measures.

Delta is more infectious than the original strain of coronavirus, and even countries which had successful mass vaccination programs, like UK, have to deal with an increasing number of new COVID-19 cases.

It looks that people need to have a higher level of antibodies to protect themselves against Delta compared to the original strain, but the situation develops fast and any data on this matter is preliminary.

Investors have been previously concerned about future revenues of vaccine producers, but it looks that the world may need coronavirus vaccines for years to come which is bullish for Moderna.

What’s Next For Moderna Stock?

Analysts expect that Moderna will report earnings of $24.57 per share this year and earnings of $18.2 per share in the next year, so the stock is trading at 13 forward P/E.

It should be noted that analyst estimates have been trending lower in recent weeks, but problems with the Delta variant of coronavirus may push estimates for 2022 to higher levels.

The situation with coronavirus remains highly volatile and it is difficlut to make accurate predictions about the spread of the virus and the demand for vaccines. However, Moderna’s current valuation looks conservative even if we account for uncertainty, so the stock has decent chances to continue its upside move.

I’d also note that shares of vaccine makers may face an influx of money from traders who are searching to hedge their bullish bets on the general market since vaccine stocks will likely get an additional boost in case the situation with COVID-19 gets worse.

For a look at all of today’s economic events, check out our economic calendar.

Is There a Next Housing Bubble That Will Make Gold Shine?

House prices are surging. As the chart below shows, the S&P/Case-Shiller U.S. National Home Price Index has reached 239 in February 2021, the highest number in history and about 30% higher than during the 2006 peak.

What’s more, the National Home Price Index has jumped 12% year-over-year in February , which is the highest annualized gain since January 2006 when the housing bubble started deflating as can be seen in the chart below. At the same time, inventory in many regions has hit record lows.

Not surprisingly, some analysts started to worry about the formation of the next housing bubble . The previous one led to the global financial crisis . However, at least some part of the recent increases can be explained by other factors than mere expectations of price increases, which characterizes a bubble.

The mortgage rates plunged thanks to the Fed’s zero-interest-rate policy and accommodative monetary policy . The easy fiscal policy with stimulus checks also added fuel to the fire, especially given that people couldn’t spend money on services, so they spent more on housing.

The demographic factors also helped to move prices up. Many Millennials have just entered the prime home-buying age, and the pandemic made a lot of people demand more space as they work remotely.

In other words, the recent surge in prices is likely a result of an imbalance between tight supply (that rises too slowly to meet booming demand fueled by low interest rates ) and income growth rather than an irrational exuberance. Furthermore, lending standards are also tighter now. Please take a look at the chart below, which shows the home price index vis-à-vis the GDP (presented also as an index).

As one can see, in the 2000s there was a clear, huge divergence between the pace of GDP growth and the pace of home prices’ appreciation that lasted a few years before the bubble burst. But since the end of the Great Recession , the growth in house prices was below the GDP growth. Therefore, I would say that there is no bubble in the housing market. Not yet, at least – house prices started to diverge from GDP growth during the pandemic recession …

Hence, it would be smart to monitor the housing market carefully. However, so far, gold bulls shouldn’t count on the housing bubble and its burst as important factor that could support the price of the yellow metal. Nevertheless, the recent ultra-low real interest rates and high inflation should support both: gold and houses . After all, they are both hard assets sensitive to interest rates and are being eagerly bought during inflationary periods.

More importantly, despite the fact that it’s maybe too early to call the national bubble in the housing market (although some locations are really hot), in many markets there are bubble-like conditions. Just think about soaring stock market indices reaching one record after another. Or negative-yielding bonds worth about $18 trillion. Or surging used car prices that have just hit an all-time high. Or lumber that has become America’s hottest commodity.

Or Dogecoin, a cryptocurrency that was created as a joke. It has gained about 8,500% this year, despite the recent sell-off in the cryptocurrency market. As a popular tweet commented on this, “Moderna created a lifesaving vaccine in record time and is worth $70 billion. Dogecoin became a meme and is worth $87 Billion.”

The widespread character of these price increases is the reason why some analysts refer to the “everything bubble”. It might be an exaggeration, but the scope of bubble-like conditions clearly shows that markets are awash in liquidity. All this new money supply and excess liquidity simply entered the economy, exerting inflationary pressure across the board and boosting mainly risk assets.

Indeed, there is inflation, but still mainly in the asset markets, not in the consumer sphere. However, this is changing, as the April CPI reading has clearly indicated. Producer/commodity inflation could advance into the next stage in which consumer prices are also generally increasing. Inflated asset valuations and rising prices of goods suggest that caution is warranted, and it would be smart to allocate some portion of the investment portfolio toward gold.

The bottom line is that the global expansion will continue, which is bad for gold. However, the growth is fueled by excessive liquidity and ultra-low interest rates, which also creates inflationary pressure and bubble-like conditions. Gold could be supported by all this – it may even thrive if inflation turns out to be higher and more lasting than it’s widely believed.

Thank you for reading today’s free analysis. We hope you enjoyed it. If so, we would like to invite you to sign up for our free gold newsletter . Once you sign up, you’ll also get 7-day no-obligation trial of all our premium gold services, including our Gold & Silver Trading Alerts. Sign up today!

For a look at all of today’s economic events, check out our economic calendar.

Arkadiusz Sieron, PhD
Sunshine Profits: Effective Investment through Diligence & Care.

 

Why Moderna Stock Is Up By 10% Today

Moderna Video 07.06.21.

Moderna Stock Rallies As Company Seeks Approval For The Use Of Its Vaccine In Teens

Shares of Moderna gained additional upside momentum and moved to new yearly highs after the company submitted applications to EU and Canada’s regulators for authorization of the expanded use of its COVID-19 vaccine in teens.

The company wants to file for an emergency use authorization in various countires for the use of its vaccine in people aged 12 to 17.

As vaccination process continues, the focus slowly shifts from high-risk groups to the rest of population in developed countries. Vaccination of teens aged 12 – 17 could be an important step to get back to normal during the next school year, so Moderna is about to enter another important market segment.

What’s Next For Moderna?

Analyst estimates for Moderna’s earnings continue to rise week after week. Currently, analysts expect that Moderna will report earnings of $25.31 per share in 2021 and $18.65 per share in 2022.

This means that the stock is trading at 12 forward P/E for 2022 despite the strong upside move that took the company’s shares from $105 at the start of this year to the current levels near $225.

Moderna remains cheaply valued by modern standards, but the discount could be explained by lack of earnings visibility. It is obvious that Moderna will have a great 2021. The next year also looks good, especially in case Moderna gets approval for the use of its vaccine in teens. Judging by recent trading action, the market believes that the company should have no problems on this front.

However, it’s hard to predict Moderna’s performance in 2023 – 2024 as it will depend on the development of the coronavirus pandemic and demand for vaccination. At this point, vaccination programs in less developed countries are progressing slowly, which means that demand for vaccines will remain strong in the next few years. Such demand will likely get financial support from international institutions as the world needs to eliminate the pandemic and destroy virus’ chances for new mutations. This scenario is bullish for Moderna shares.

For a look at all of today’s economic events, check out our economic calendar.

Top Scientists Question the Need for COVID-19 Booster Shots

By Julie Steenhuysen and Kate Kelland

In interviews with Reuters, more than a dozen influential infectious disease and vaccine development experts said there is growing evidence that a first round of global vaccinations may offer enduring protection against the coronavirus and its most worrisome variants discovered to date.

Some of these scientists expressed concern that public expectations around COVID-19 boosters are being set by pharmaceutical executives rather than health specialists, although many agreed that preparing for such a need as a precaution was prudent.

They fear a push by wealthy nations for repeat vaccination as early as this year will deepen the divide with poorer countries that are struggling to buy vaccines and may take years to inoculate their citizens even once.

“We don’t see the data yet that would inform a decision about whether or not booster doses are needed,” said Kate O’Brien, director of the Department of Immunization, Vaccines and Biologicals at the World Health Organization (WHO).

O’Brien said the WHO is forming a panel of experts to assess all variant and vaccine efficacy data and recommend changes to vaccination programs as needed.

Pfizer Inc Chief Executive Albert Bourla has said people will “likely” need a booster dose of the company’s vaccine every 12 months – similar to an annual flu shot – to maintain high levels of immunity against the original SARS-CoV-2 virus and its variants.

“There is zero, and I mean zero, evidence to suggest that that is the case,” countered Dr. Tom Frieden, former director of the U.S. Centers for Disease Control and Prevention.

“It’s completely inappropriate to say that we’re likely to need an annual booster, because we have no idea what the likelihood of that is,” Frieden, who now leads the global public health initiative Resolve to Save Lives, said of Pfizer’s assertions on boosters.

Pfizer, responding to the criticism, said it expects a need for boosters while the virus is still circulating widely. That could change once the pandemic is more firmly under control, a company spokeswoman said.

Moderna Inc CEO Stephane Bancel aims to produce a vaccine by the fall that targets a variant first identified in South Africa and expects regular boosters will be needed.

The United States is preparing to have such doses on hand for Americans, while the European Union, Britain and Israel have ordered new supplies of COVID-19 vaccines to deploy as protective boosters.

Some health experts, including Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations (CEPI) that has funded many vaccine projects, say vaccine makers are right to plan ahead for boosters given the uncertainty over what will be needed in the long run.

Governments can then decide for themselves whether to buy the products, he said.

“A LITTLE EVIDENCE”

Pfizer and German partner BioNTech SE have so far found that their shot remains more than 91% effective for six months after people received their second dose, compared with nearly 95% demonstrated in their clinical trial. The companies will track how robust the protection remains over time.

Dr. William Gruber, Pfizer’s senior vice president of vaccine clinical research and development, told Reuters earlier this month the prediction for yearly boosters was based on “a little evidence” of a decline in immunity over those six months.

Pfizer expects the COVID-19 vaccine to be a major revenue contributor for years, and has forecast sales of $26 billion from the shot in 2021. Global spending on COVID-19 vaccines and booster shots could total $157 billion through 2025, according to U.S. health data firm IQVIA Holdings.

Moderna President Stephen Hoge expects boosters will be needed to keep immunity levels high, due in part to vaccine hesitancy, as an estimated 30% of the U.S. population may not agree to be vaccinated. As long as the virus is circulating widely, people at high risk of severe illness may need to boost their immune protection, Hoge said.

“All governments are in conversations with (Moderna) and other companies about boosters,” he said.

BROADER IMMUNITY?

Late last year, scientists were optimistic that highly effective vaccines could quickly curb the global pandemic that has battered economies and killed more than 3.4 million people.

Those hopes dimmed by February with evidence that mutant versions of the virus might evade protection offered by vaccines. Laboratory studies showed that the South African variant could produce six to eight-fold reductions in antibody levels among people vaccinated with the Pfizer or Moderna vaccines.

Clinical trial data also showed that vaccines from AstraZeneca Plc, Johnson & Johnson and Novavax Inc were less effective at preventing infections in South Africa, where the variant is widespread.

These studies spurred drug companies to start testing booster doses of their vaccines and to develop shots that target specific variants of the virus.

However, more recent research suggests that the Moderna and Pfizer/BioNTech vaccines produce high levels of protective antibodies to create a “cushion effect” against the known variants, said Dr. Anthony Fauci, head of the National Institutes of Allergy and Infectious Diseases (NIAID) and a top White House adviser.

And antibodies – which block the coronavirus from attaching to human cells – do not tell the whole story. Several studies suggest that T cells – a type of white blood cell that can target and destroy already infected cells – may help prevent severe COVID-19 and hospitalization.

NIAID researchers found that T cells in the blood of people who recovered from the original virus could still fight off infections caused by the concerning variants found in the UK, South Africa and Brazil.

“It’s quite possible” that boosters would not be needed, Fauci told Reuters. “It is conceivable that the variants will not be as much a problem with a really good vaccine as we might have anticipated.”

Nevertheless, health authorities in the United States, Britain and Europe are assuring their populations that a new round of shots will be available if needed, with many nations still desperate for vaccine supplies.

“It’s a huge concern that … wealthy countries would begin administering booster doses and further constraining supply of people’s first dose of vaccine,” said Rajeev Venkayya, head of global vaccines for Takeda Pharmaceutical Co.

Dr. Monica Gandhi, an infectious disease doctor at the University of California, San Francisco, said ultimately, decisions on whether boosters will be needed “will best be made by public health experts, rather than CEOs of a company who may benefit financially.”

(Reporting by Julie Steenhuysen in Chicago and Kate Kelland in London; Additional reporting by Michael Erman in Maplewood, N.J.; Editing by Michele Gershberg and Bill Berkrot)

Why Shares Of Moderna Are Down By 5% Today?

Moderna Video 06.05.21.

Moderna Stock Moves Lower As Q1 Revenue Misses Estimates

Shares of Moderna found themselves under pressure after the company released its first-quarter results.

Moderna reported revenue of $1.94 billion and earnings of $2.84 per share, beating analyst estimates on earnings and missing them on revenue. It looks that the market was not ready to tolerate the revenue miss, and it weighed heavily on Moderna stock.

The bar was set high for the company whose shares were up by more than 60% year-to-date before the release of the quarterly report. In addition, shares of  vaccine makers found themselves under pressure after U.S. signaled that it would support a waiver for vaccine IP rights at the WTO.

EU has already stated that it was ready to discuss waving COVID-19 vaccines patents, which is a worrisome development for investors. At the same time, it remains to be seen whether any decisions will be made in the near term.

What’s Next For Moderna?

The sell-off in Moderna shares was triggered by IP waiver-related fears and a revenue miss. IP waiver-related fears probably served as the main catalyst for the current sell-off as other vaccine makers like BioNTech and Pfizer also found themselves under pressure.

Currently, analysts expect that Moderna will report earnings of $23.27 per share in 2021 and $16.58 per share in 2022 so the stock is trading at about 9 forward P/E for 2022 which is very cheap in today’s market environment.

However, there is a lot of uncertainty regarding future profits, and recent discussions about waiving IP rights add another layer of uncertainty. At the same time, it looks increasingly likely that at least some part of the vaccine revenue will be recurring as people may need regular shots to protect themselves against COVID-19.

In this light, Moderna shares may soon attract speculative traders and investors who will want to use the current pullback as an opportunity to buy the stock at lower levels.

For a look at all of today’s economic events, check out our economic calendar.

Will Earnings Season Bring Volatility To The Stock Market?

The Commerce Department last week reported that the U.S. economy grew at a +6.4% annual rate in the first quarter, slightly below estimates but still strong. If it would have come in real hot and much higher bears would have pointed to fanning the inflation flames even further.

This mindset of “bad-news-could-be-good-news” is helping to keep the stock market at or near all-time highs. If economic data somewhat disappoints it means the Fed stay dovish and accommodative for longer.

Fundamental analysis

That might be important to keep in mind as April data starting this week is expected to be extremely good. The April Employment Report is due next Friday and with upper-end of Wall Street estimates look for upwards of +1 million new jobs being added. Other key April data next week includes the ISM Manufacturing Index on Monday, and the ISM Non-Manufacturing Index on Wednesday.

employment

If the data comes in better than expected the bears will win the nearby battle and have the upper hand when talking higher inflation and the Fed perhaps tightening sooner than anticipated. So this week could be a bit tricky whereas “disappointing-data” could actually be digested as a win for the bulls and “strong data” a win for the bears.

The earnings calendar is packed again next week with big names including Activision Blizzard, Adidas, AllState, Cerner, Cigna, CVS, Dominion Energy, Enbridge, Etsy, Hilton Worldwide, Moderna, Monster Beverage, Nintendo, PayPal, Peloton, Pfizer, Rocket Companies, Square, TMobile, Wayfair, and Zoetis.

COVID-19

Checking in on U.S. progress against Covid-19, the number of adults that have received at least one dose is around 60%-65%, depending on the source. Global cases continue to rise led by India, where new infections have been hitting new record highs every day for weeks now. The country reported a staggering 380k new infections and 3,645 new deaths on Thursday while less than 10% of the population has been vaccinated.

Bottom line, the global restart will not be synchronized like many bulls had hoped would be the case and global growth may continue to struggle. At the moment the U.S. market doesn’t seem to care. It will be interesting to see if increasing inflation and continued global headwinds will eventually come home to roost.

SP500 technical analysis

SP500 earnings season

Earnings season can bring volatility to the stock market. At the beginning of May, cycles turn to the downside. Note, this is only a timing tool and it never shows the amplitude or strength of the move. When cycles are topping, it means we can expect a move down or choppy trading. This is it.

But relying on cycles only is not a good idea. Insider Accumulation Index shows bearish divergence on a daily chart. At the same time, Advanced Decline Line is still strong. The key resistance is around 4250 at the moment. I believe earning season can bring a profit booking to the stock market. If that happens, watch 4000 – 39500. It was a massive resistance and now it might turn into support. Intermarket Forecast is neutral. But if it turns to the downside, we will finally see a pullback in SP500.

For a look at all of today’s economic events, check out our economic calendar.

Earnings to Watch Next Week: ON Semiconductor, Ferrari, General Motors and Moderna in Focus

Earnings Calendar For The Week Of May 3

Monday (May 3)

IN THE SPOTLIGHT: ON SEMICONDUCTOR

ON Semiconductor, a semiconductors supplier company, is expected to report its first-quarter earnings of $0.34 per share, which represents year-over-year growth of over 240% from $0.10 per share seen in the same quarter a year ago.

The Phoenix, Arizona-based company’s revenue would grow over 14% to $1.4 billion.

“The company is the only one in our coverage to see weaker gross margins cycle to cycle. Notably, this is happening despite an improvement in end-market mix toward industrial and autos and away from consumer and computing, where ON has become more selective in recent quarters,” noted Craig Hettenbach, equity analyst at Morgan Stanley.

“We like the message from the new CEO of improving mix of the business but think this has already been reflected in meaningful multiple expansion in the stock. Another thing to consider is the potential for lost revenue as the company deemphasizes some products.”

TAKE A LOOK AT OUR EARNINGS CALENDAR FOR THE FULL RELEASES FOR THE MAY 3

Ticker Company EPS Forecast
ENBL Enable Midstream Partners $0.17
EL Estée Lauder $1.28
WEC Wisconsin Energy $1.47
EPD Enterprise Products Partners $0.50
ON ON Semiconductor $0.34
ITRI Itron $0.40
ALXN Alexion Pharmaceuticals $3.08
L Loews $0.95
CNA CNA Financial $0.95
EPRT Essential Properties Realty Trust Inc $0.29
VRNS Varonis Systems -$0.13
QGEN Qiagen $0.63
RMBS Rambus $0.28
WWD Woodward $0.82
REGI Renewable Energy $0.20
IRBT Irobot $0.06
SCI Service International $0.98
ITUB Itau Unibanco $0.12
FN Fabrinet $1.15
CAR Avis Budget -$2.38
JKHY Jack Henry Associates $0.86
O Realty Ome $0.85
BRX Brixmor Property $0.40
UE Urban Edge Properties $0.22
AWK American Water Works $0.73
NSP Insperity $1.56
APO Apollo Global Management $0.59
RBC Regal Beloit Corporation $1.68
ADC Agree Realty $0.83
CR Crane $1.31
OGS One Gas $1.78
CHGG Chegg $0.31
CVI CVR Energy -$1.23
OHI Omega Healthcare Investors $0.82
XPO XPO Logistics $0.93
FLS Flowserve $0.20
CBT Cabot $0.97
LEG Leggett & Platt $0.41
FANG Diamondback Energy $1.89
SHO Sunstone Hotel Investors -$0.15
KMT Kennametal $0.21
SEDG Solaredge Technologies Inc $1.01
VNO Vornado Realty $0.63
WMB Williams Companies $0.28
AWR American States Water $0.48
MWA Mueller Water Products $0.14
MOS Mosaic $0.50
CC Chemours Co $0.68
LGND Ligand Pharmaceuticals $1.05
CORT Corcept Therapeutics $0.21
CIB Bancolombia $0.34
SANM Sanmina $0.82
EGOV NIC $0.24
AMG Affiliated Managers $4.24

Tuesday (May 4)

IN THE SPOTLIGHT: FERRARI

Ferrari, an Italian luxury sports car manufacturer, is expected to report its first-quarter earnings of $1.26 per share, which represents year-over-year growth of over 27% from $0.99 per share seen in the same quarter a year ago.

The company which is known for its prancing horse logo would post revenue growth of more than 24% to around $1.27 billion

“We find the long-term stability of Ferrari’s revenue, addressable market growth, expansive profit margin, and solid returns on invested capital throughout economic cycles to be compelling reasons to invest at the right price,” noted Richard Hilgert, senior equity analyst at Morningstar.

“Because of its exclusive clientele of high-net-worth individuals, we believe the company will show resiliency during periods of economic uncertainty, such is currently the case with the coronavirus pandemic. While we are not entirely averse to paying up for stocks like Ferrari that possess a wide economic moat and stable economic profits through business cycles, we think Ferrari stock will regularly trade at rich, luxury goods valuation multiples.”

TAKE A LOOK AT OUR EARNINGS CALENDAR FOR THE FULL RELEASES FOR THE MAY 4

Ticker Company EPS Forecast
ARNC Arconic Inc $0.29
CMI Cummins $3.46
CVS CVS Health $1.71
MPLX MPLX $0.61
PFE Pfizer $0.79
SYY Sysco $0.20
TRI Thomson Reuters USA $0.40
MPC Marathon Petroleum -$0.72
NS NuStar Energy $0.28
BR Broadridge Financial Solutions $1.67
ETRN Equitrans Midstream Corp $0.19
DD DuPont $0.77
LDOS Leidos $1.49
D Dominion Resources $1.08
EXPD Expeditors International Of Washington $1.00
RACE Ferrari $1.26
LPX Louisiana Pacific $2.67
CVLT Commvault Systems $0.49
ZBH ZIMMER BIOMET HDG. $1.51
UAA Under Armour Inc $0.04
XYL Xylem $0.37
UA Under Armour C share $0.04
INGR Ingredion $1.62
SEE Sealed Air $0.71
INCY YTE $0.65
BERY Berry Plastics $1.31
LGIH LGI Homes $2.37
BG Bunge $1.55
PCRX Pacira $0.58
RGEN Repligen $0.43
VSH Vishay Intertechnology $0.45
LANC Lancaster Colony $1.26
CTLT Catalent $0.76
KKR KKR & Co LP $0.62
CWH Camping World Holdings $0.54
RHP Ryman Hospitality Properties -$0.78
AME Ametek $1.02
WLK Westlake Chemical $1.56
IAA IAA Inc $0.46
VMC Vulcan Materials $0.41
GPN Global Payments $1.77
IPGP IPG Photonics $1.07
HSIC Henry Schein $0.83
IT Gartner $1.01
CRL Charles River Laboratories $2.19
HEP Holly Energy Partners $0.48
NXST Nexstar Broadcasting $3.11
MLM Martin Marietta Materials $0.51
LAMR Lamar Advertising $1.17
IDXX Idexx Laboratories $1.72
FSS Federal Signal $0.33
MIC Macquarie Infrastructure $0.48
NNN National Retail Properties $0.64
SABR Sabre -$0.51
MYGN Myriad Genetics -$0.10
BEN Franklin Resources $0.74
ZBRA Zebra Technologies $4.41
COP ConocoPhillips $0.57
ETN Eaton $1.25
HI Hillenbrand $0.92
CMP Compass Minerals International $0.72
VRSK Verisk Analytics $1.25
JBGS JBG SMITH Properties $0.31
LYFT Lyft Inc -$0.54
AMCR Amcor PLC $0.18
LSI LIFE STORAGE $1.01
STAG STAG Industrial $0.48
XP XP Inc $0.20
RPAI Retail Properties Of America $0.20
OUT Outfront Media -$0.17
MANT ManTech International $0.83
MED Medifast $2.72
PAYC Paycom Software $1.42
AKAM Akamai $1.30
LSCC Lattice Semiconductor $0.19
ARWR Arrowhead Research $0.34
AFG American Financial $1.74
TTEC TeleTech $1.00
ANET Arista Networks $2.38
GMED Globus Medical $0.36
INSP Inspire Medical Systems Inc -$0.65
ENLC EnLink Midstream -$0.02
IOSP Innospec $1.02
PVG Pretium Resources $0.21
HLF Herbalife $1.06
RDN Radian $0.67
TMUS T-Mobile Us $0.53
ESE ESCO Technologies $0.55
HST Host Hotels & Resorts -$0.15
PKI PerkinElmer $3.03
BKH Black Hills $1.60
ATVI Activision Blizzard $0.69
XLNX Xilinx $0.75
WTS Watts Water Technologies $0.98
AMRC Ameresco $0.10
CZR Caesars Entertainment -$1.77
MCY Mercury General $1.25
MRCY Mercury Systems $0.63
CPK Chesapeake Utilities $1.83
AIZ Assurant $1.96
LPSN LivePerson -$0.14
DOOR Masonite International $1.78
PXD Pioneer Natural Resources $1.82
EQC Equity Commonwealth $0.01
PEAK Healthpeak Properties Inc $0.39
DVN Devon Energy $0.35
RNG RingCentral $0.25
EPAY Bottomline Technologies $0.27
MTCH Match Group $0.46
JAZZ Jazz Pharmaceuticals $3.69
PRU Prudential Financial $2.68
NMIH NMI $0.59
DLB Dolby Laboratories $0.67
HASI Hannon Armstrong Sustnbl Infrstr Cap $0.40
MPWR Monolithic Power Systems $1.33
H Hyatt Hotels -$1.33
WU Western Union $0.45
DEI Douglas Emmett $0.43
EXAS Exact Sciences -$1.04
ALGT Allegiant Travel -$2.59
PTCT PTC Therapeutics -$1.59
Z Zillow $0.26
NRZ New Residential Investment $0.34
LITE Lumentum Holdings Inc $1.42
SU Suncor Energy USA $0.44
MELI MercadoLibre $0.40
HAE Haemonetics $0.67
TDG TransDigm $2.52
IOVA Iovance Biotherapeutics -$0.48
QTRX Quanterix -$0.32
VST Victory Square Tech -$2.04
GRFS Grifolsbarcelona $0.23
BBD Banco Bradesco $0.11
CHT Chunghwa Telecom $0.33

Wednesday (May 5)

IN THE SPOTLIGHT: GENERAL MOTORS

The auto manufacturer is expected to report its first-quarter earnings of $1.02 per share, which represents year-over-year growth of over 64% from $0.62 per share seen in the same quarter a year ago. The Detroit, Michigan-based company would post revenue growth of about 2% to around $33.3 billion.

“We are Overweight based on GM’s diversified portfolio, with multiple ways for GM to enhance shareholder value, through: EVs, ICE and Autonomy. GM also has leading North American margins, generates strong cash flow, and has a robust balance sheet,” noted Adam Jonas, equity analyst at Morgan Stanley.

“We believe that the market is underestimating the SOTP of the GM enterprise via: 1) Legacy ICE, 2) GM EV, 3) GM’s Ultium Battery business, 4) China JVs, 5) GM Finco, 6) GM Cruise, 7) hidden franchise value in brands such as Corvette and 8) GM Connected Services. GM management has a proven track record to allocate capital away from structurally challenged areas towards re-positioning the business model.”

TAKE A LOOK AT OUR EARNINGS CALENDAR FOR THE FULL RELEASES FOR THE MAY 5

Ticker Company EPS Forecast
UTHR United Therapeutics $2.60
HLT Hilton Worldwide $0.05
PNW Pinnacle West Capital $0.28
CERN Cerner $0.74
HFC HollyFrontier -$0.45
ODP Office Depot $1.02
AEIS Advanced Energy Industries $1.27
OMI Owens Minor $0.97
DNB Dun & Bradstreet $0.21
SMG Scotts Miracle-Gro $5.51
DOC Physicians Realty $0.27
WRK WESTROCK $0.62
GOLD Randgold Resources $0.26
TT Trane Technologies PLC $0.62
CIM Chimera Investment $0.31
SRE Sempra Energy $2.60
NYT New York Times $0.15
AVA Avista $0.85
ROCK Gibraltar Industries $0.61
SPR Spirit AeroSystems -$0.93
PEG Public Service $1.12
BWA Borgwarner $0.92
GM General Motors $1.02
JLL Jones Lang LaSalle $0.58
SBGI Sinclair -$2.18
EMR Emerson Electric $0.90
NI NiSource $0.77
ABC AmerisourceBergen $2.50
BRKR Bruker $0.32
FUN Cedar Fair -$1.89
IONS Ionis Pharmaceuticals -$0.47
EXC Exelon $0.42
WAT Waters $1.57
CDW CDW $1.54
CRTO Criteo $0.50
CLH Clean Harbors $0.26
HZNP Horizon Pharma $0.19
SPWR SunPower $0.00
FLEX Flextronics International $0.36
BKNG Booking Holdings Inc -$7.26
QLYS Qualys $0.69
ATO Atmos Energy $2.05
ALL Allstate $3.85
GIL Gildan Activewear USA $0.20
KLIC Kulicke And Soffa Industries $1.20
PTVE Pactiv Evergreen $0.03
LNC Lincoln National $1.48
TTGT TechTarget $0.37
RLJ RLJ Lodging -$0.26
ADPT Adeptus Health -$0.41
PRI Primerica $2.38
ZNGA Zynga $0.09
UNM Unum $1.01
HPP Hudson Pacific Properties $0.46
RUN Sunrun Inc -$0.03
WTRG Essential Utilities Inc $0.66
EPR EPR Properties $0.44
FLT Fleetcor Technologies $2.70
QRVO Qorvo $2.44
UGI UGI $1.72
CDAY Ceridian HCM Holding Inc $0.09
CW Curtiss-Wright $1.30
FMC FMC $1.52
CTSH Cognizant Technology Solutions $0.94
SIMO Silicon Motion Technology $0.94
AEL American Equity Investment Life $0.59
ANSS Ansys $0.85
MET MetLife $1.48
XEC Cimarex Energy $1.70
VAC Marriottacations Worldwide -$0.29
SRC Spirit Realty Capital New $0.73
TNDM Tandem Diabetes Care -$0.15
SJI South Jersey Industries $1.19
EQT EQT $0.28
ETSY ETSY Inc $0.84
MFC Manulife Financial USA $0.59
NBIX Neurocrine Biosciences $0.46
CCMP Cabot Microelectronics $1.94
EQH AXA Equitable Holdings Inc $1.23
MRO Marathon Oil $0.14
CF CF Industries $0.57
STN Stantec USA $0.42
RYN Rayonier $0.08
RSG Republic Services $0.86
FRT Federal Realty Investment $1.02
PDCE PDC Energy $0.83
PYPL PayPal $1.01
BFAM Bright Horizons Family Solutions $0.10
BE Bloom Energy Corp -$0.08
LBTYA Liberty Global Class A Ordinary Shares $0.09
HR Healthcare Realty $0.42
MTG MGIC Investment $0.42
NUVA NuVasive $0.33
ALB Albemarle $0.79
STAA STAAR Surgical $0.02
CPA Copa -$2.21
NUS Nu Skin Enterprises $0.72
TWO Two Harbors Investment $0.21
ACAD Acadia Pharmaceuticals -$0.54
RCII Rent-A-Center $1.11
LOPE Grand Canyon Education $1.67
ORA Ormat Technologies $0.40
KW Kennedy Wilson $0.27
LHCG LHC $1.26
SLF Sun Life Financial USA $1.08
FOXA Twenty-First Century Fox $0.57
FNV Franco Nevada $0.79
QTWO Q2 $0.07
UBER Uber -$0.56
SBRA Sabra Health Care Reit $0.40
RKT Rocket Cos. Inc. $0.89
MDU MDU Resources $0.20
TRMB Trimble Navigation $0.56
GDOT Green Dot $0.93
APA Apache $0.69
HUBG HUB $0.46
KAI Kadant $1.36
SBH Sally Beauty $0.16
BCH Banco De Chile $0.40
DAR Darling Ingredients $0.56
RARE Ultragenyx Pharmaceutical -$1.25
TRNO Terreno Realty $0.39
CCU Compania Cervecerias Unidas $0.32
CENTA Central Garden Pet $1.08
RCKT Rocket Pharma -$0.77
CUB Cubic $0.41
AVNS Avanos Medical Inc $0.18
FMS Fresenius Medical Care $0.45
UGP Ultrapar Participacoes $0.04
ELP Companhia Paranaense De Energia $0.03
LBTYK LIBERTY GLOBAL $0.09
FOX Twenty First Century Fox $0.58
NVO Novo Nordisk A Fs $0.79
BAK Braskem $1.38
AEBZY Anadolu Efes ADR $0.01
OMVJF OMV $0.97
SRPT Sarepta Therapeutics -$2.01
VIV Telefonica Brasil $0.13
ES Eversource Energy $1.10
GBT BMTC Group -$1.02

Thursday (May 6)

IN THE SPOTLIGHT: MODERNA

Moderna Inc, an American biotech company focused on drug discovery, is expected to report its first-quarter earnings of $2.36 per share, up about 700% from the same quarter a year ago. The Massachusetts-based biotechnology company’s revenue would surge to $1.97 billion.

“We are Equal-weight Moderna. While we believe there is long-term upside for Moderna, we believe the significant valuation increase associated with the success of the COVID-19 vaccine limits the near-term upside,” noted Matthew Harrison, equity analyst at Morgan Stanley.

“The company has taken an industrialized approach to developing mRNA-based therapeutics and has rapidly generated a broad pipeline of 21 programs, 11 of which have entered clinical development. We believe Moderna’s mRNA drug development platform is more diversified and scalable compared with competitors and is validated through broad partnerships with Merck and AstraZeneca. We see vaccines and rare diseases as the key valuation drivers of the company.”

TAKE A LOOK AT OUR EARNINGS CALENDAR FOR THE FULL RELEASES FOR THE MAY 6

Ticker Company EPS Forecast
PZZA Papa John’s International $0.55
AY Atlantica Yield -$0.13
SUN Sunoco $0.69
TECH Bio Techne $1.50
ZTS Zoetis $1.04
EPAM EPAM Systems $1.69
APTV Aptiv PLC $0.77
MGA Magna International USA $1.59
VER VEREIT $0.78
WCC Wesco International $0.76
BUD Anheuser-Busch $0.48
IRM Iron Mountain $0.64
LIN Linde PLC $2.26
BDX Becton, Dickinson and Co. $3.04
AES AES $0.31
BLD TopBuild Corp $1.93
HWM Howmet Aerospace Inc $0.20
BIP Brookfield Infrastructure $0.87
PENN Penn National Gaming $0.28
K Kellogg $0.95
PWR Quanta Services $0.74
BLL Ball $0.67
STWD Starwood Property $0.51
SEAS SeaWorld Entertainment -$0.83
CNP CenterPoint Energy $0.50
ALE Allete $1.11
WD Walker & Dunlop $2.01
COMM CommScope $0.31
PRLB Proto Labs $0.37
VG Vonage $0.05
AMRS Amyris -$0.16
BKI Black Iron Inc. $0.51
PBH Prestige Brands $0.79
W Wayfair Inc. $0.27
REGN Regeneron Pharmaceuticals $8.79
NSIT Insights $1.44
FIS Fidelity National Information Services $1.25
TRGP Targa Resources $0.15
EVOP EVO Payments Inc $0.12
CNQ Canadian Natural Resource USA $0.67
MUR Murphy Oil -$0.16
XRAY Dentsply International $0.55
IDCC InterDigital -$0.01
EVRG Evergy Inc $0.47
CAH Cardinal Health $1.57
EPC Edgewell Personal Care $0.62
THS TreeHouse Foods $0.35
STOR STORE Capital Corp $0.45
HAIN Hain Celestial $0.38
ADNT Adient PLC $0.59
MT Arcelormittal $1.57
OGE OGE Energy $0.18
NJR New Jersey Resources $1.17
MRNA Moderna Inc $2.36
BCRX BioCryst Pharmaceuticals -$0.26
FOCS Focus Financial Partners Inc $0.86
HII Huntington Ingalls Industries $2.52
IIVI Ii Vi $0.88
TPR Tapestry Inc $0.30
ARW Arrow Electronics $2.27
BLDR Builders Firstsource $0.81
INSM Insmed -$1.02
BECN Beacon Roofing Supply $0.01
NWSA News Corp $0.06
XLRN Acceleron Pharma -$0.83
QDEL Quidel $4.87
IHRT Iheartmedia -$0.44
AL Air Lease $1.01
Y Alleghany $4.65
AVLR Avalara Inc -$0.11
ALTR ALTAIR ENGINEERING $0.20
SEM Select Medical $0.65
CGNX Cognex $0.35
LYV Live Nation Entertainment -$1.77
TDC Teradata $0.46
CABO Cable One Inc $10.22
KWR Quaker Chemical $1.51
APLE Apple Hospitality $0.03
CLNE Clean Energy Fuels $0.01
ICUI ICU Medical $1.53
MCHP Microchip Technology $1.74
MTX Minerals Technologies $1.07
PTON Peloton Interactive, Inc. -$0.11
ANGI Angie’s List -$0.04
ENV Envestnet $0.61
CDK Cdk Global $0.68
REG Regency Centers $0.75
AIG AIG $0.99
SQ Square $0.16
MSI Motorola Solutions Msi $1.62
RVLV Revolve $0.13
SFM Sprouts Farmers Market $0.62
OLED Universal Display $0.67
PODD Insulet $0.06
AMH American Homes 4 Rent $0.31
PK Park Hotels & Resorts Inc -$0.55
EXPE Expedia -$2.52
TRIP TripAdvisor -$0.31
LNT Alliant Energy $0.67
FOXF Fox Factory $0.82
HTA Healthcare Of America $0.43
EXEL Exelixis $0.05
POST Post $0.55
CSOD Cornerstone OnDemand $0.42
SYNA Synaptics $1.87
ED Consolidated Edison $1.36
DBX Dropbox $0.30
IRTC iRhythm Tech -$0.87
DRH DiamondRock Hospitality -$0.14
MCK McKesson $5.01
YELP Yelp -$0.26
DIOD Diodes $0.78
CWK Cushman & Wakefield plc -$0.04
RGA Reinsurance Of America $0.07
STMP Stamps $1.63
EOG EOG Resources $1.50
BAP Credicorp USA $2.37
AAON AAON $0.24
MTD Mettler Toledo International $5.65
PCTY Paylocity $0.66
BCC Boise Cascade $2.50
NFG National Fuel Gas $1.21
MTZ MasTec $0.77
TPL Texas Pacific Land $5.77
FNF Fidelity National Financial $1.28
PHI Philippine Long Distance Telephone $0.61
NWS News $0.05
CYRX Cryoport Inc -$0.21
PPL PPL $0.61
NRG NRG Energy $1.64
NKTR Nektar Therapeutics -$0.75
GLUU Glu Mobile $0.07
PLUG Plug Power -$0.08
MNST Monster Beverage $0.61
NTLA Intellia Therapeutics Inc -$0.66
CTRE CareTrust REIT $0.36
ADT ADT $0.15
ARNA Arena Pharmaceuticals -$2.19
SWX Southwest Gas $1.83
MIDD Middleby $1.63
MRTX Mirati Therapeutics -$2.13
JOBS 51job $0.43
PFSI Pennymac Financial Services $5.79
KRTX Karuna Therapeutics -$1.06
MGEE Mge Energy $0.81
ITCI Intra Cellular Therapies -$0.81
XNCR Xencor -$0.77
SATS EchoStar -$0.02
DRNA Dicerna Pharmaceuticals -$0.28
IGMS IGM Biosciences -$0.98
RVNC Revance Therapeutics -$1.19
PAR Par Technology -$0.37
ACIW ACI Worldwide -$0.12
AG First Majestic Silver $0.07
ING Ing Groep $0.23
GFI Gold Fields $0.64
ABEV Ambev $0.03
AGO Assured Guaranty $0.56
MMS Maximus $0.82

Friday (May 7)

Ticker Company EPS Forecast
CI Cigna $4.37
VTR Ventas $0.02
LEA Lear $2.95
MD Mednax $0.16
AMCX AMC Networks $2.01
ENB Enbridge USA $0.57
CCJ Cameco USA -$0.08
TRP Transcanada USA $0.87
LBRDK Liberty Broadband Lbrdk $1.10
SPB Spectrum Brands $0.99
LBRDA Liberty Broadband $0.85
ITT ITT $0.87
FLR Fluor New $0.04
ESNT Essent $1.22
UNVR Univar Solutions Inc $0.32
HE Hawaiian Electric Industries $0.36
RICOY Ricoh Company -$0.08
IBP Installed Building Products $1.04
TU Telus USA $0.23
SSUMY Sumitomo ADR -$0.02
CNK Cinemark -$1.47
CVE Cenovus Energy USA -$0.02
LXP Lexington Realty $0.03